LHRH antagonists having improved solubility properties

Details LHRH antagonists having improved solubility properties LHRH antagonists having improved solubility properties

2006-12-12

2006-12-12

Chism, B. Dell (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S328000

Reexamination Certificate

active

07148195

ABSTRACT:
The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. Medicaments in which the peptides according to the invention are contained can be used for the treatment of hormone-dependent tumors and hormone-influenced non-malignant disorders.

REFERENCES:
patent: 4581169 (1986-04-01), Nestor et al.
patent: 4628044 (1986-12-01), Loozen
patent: 5198533 (1993-03-01), Schally et al.
patent: 5300492 (1994-04-01), Haviv et al.
patent: 5527777 (1996-06-01), Thamm et al.
patent: 5942493 (1999-08-01), Kutscher et al.
patent: 195 44 212 (1997-06-01), None
patent: 0 328 090 (1989-08-01), None
patent: 0 413 209 (1991-02-01), None
patent: 0417454 (1991-03-01), None
patent: WO 97/19953 (1997-06-01), None
patent: WO 98/25642 (1998-06-01), None
patent: WO 00/55190 (2000-09-01), None
Dermer 1994, Another Anniversary for the War on Cancer, Bio/Technology, vol. 12, p. 320.
Haviv et al., “The Effect of NmeTyr5Substitution in Luteinizing Hormone-Releasing Hormone Antagonists”,J. Med. Chem. 36(7), 928-933, 1993.

Affiliated with

Also associated with

Rating

LHRH antagonists having improved solubility properties does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with LHRH antagonists having improved solubility properties, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LHRH antagonists having improved solubility properties will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3665798